Searched for
CUSTOM SYNTHESIS CAPACITY
Anthem Biosciences shares surge 46% since listing amid strong financial growthAnthem Biosciences shares have risen significantly since its listing. The company reported strong June quarter results, boosting investor c...- Anthem Biosciences sets IPO price band at Rs 540-570/shareAnthem Biosciences is launching its IPO from July 14-16. The price is fixed between Rs 540 to Rs 570. The IPO aims to raise Rs 3,395 crore ...
- Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...
- 5 retail favourite stocks in trouble after turning multibaggersShares of smallcap Brightcom Group, a digital marketing company, had a gravity-defying rally in 2021. The stock is still up over 800% in th...
- 3 reasons Laurus Labs is this week's stock pickLaurus Labs will benefit from the growth prospects of the global and domestic pharma indutry as spending on medicines, including Covid-19 v...
- Jefferies sees up to 21% upside in these two pharma stocksIt has a target of Rs 4,566 on Gland Pharma, valuing the stock at 36.5 times FY24 EPS, in line with its historical one-year forward of 37 t...
- Up 670% in 4 years, this API maker’s adrenaline rush is simply not endingThe stock escaped the broader selloff of March 2020 and remained unfazed in the face of the Covid 2.0 volatility, as it kept on hitting rec...
- Anupam Rasayan IPO looks fully priced: Should you subscribe?After annualising the earnings for the nine-months of FY21, Anupam Rasayan IPO demands a price-earnings (P/E) multiple of 86.
- Divi’s Labs hits all-time high after robust Q2 resultsA recent entrant to the Nifty pack, Divi’s Labs is up 82 per cent year-to-date, and has almost doubled over the last one year.
- Buy Laurus Labs, target Rs 480: HDFC SecuritiesBuy Laurus Labs at a price target of Rs 480.
- Buy Divi's Laboratories, target Rs 1,600: Axis CapitalBuy Divi's Laboratories Ltd. at a price target of Rs 1600.
- Divis to spend Rs 300 crore on expansion plans in 2018The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during th...
- Our strategy is to file 8-10 ANDAs per year: Laurus Labs founder“Shorter regulatory approval timelines mean there is a scope for new players and integrated players like us”
- Agrochem industry expected to double in next five years: Mayank Singhal, PI IndustriesThe Indian agrochem industry is expected to be between $2 billion and $2.5 billion, and is expected to double in the next five years.
- Divi’s Labs Q4 performance triggers fresh buying in the stockGaining 20%, Divi’s Labs emerged as the top gainer of the BSE healthcare index. The co’s fourth quarter performance has justified this stoc...
- Shasun Pharmaceuticals aims to be Rs 2,000 cr company by 2015Shasun Pharmaceuticals today said it aims to achieve revenues of Rs 2,000 crore by the end of 2015.
- Looking for a 50% increase in PAT: Salil Singhal, chairman, PI IndustriesIn an interview with ET Now, Salil Singhal, chairman, PI Industries, talks about their quarterly performance and margin outlook.
- Suven Life lines up $45-m expansionSuven Lifesciences, is planning to scale up its drug discovery development and support services.
- Shasun to project R&D identityChennai-based Shasun Chemicals and Drugs is aiming to change its image as a bulk drug manufacturer to one of a research-driven company in t...
- Shasun to project R&D identityThe Chennai-based Shasun Chemicals and Drugs is aiming to change its image as a bulk drug manufacturer to one of a research-driven company ...
Load More
